

LETTER

Open Access



# The kinetic glomerular filtration rate is not interchangeable with measured creatinine clearance for prediction of piperacillin underexposure in critically ill patients with augmented renal clearance

Cédric Carrié<sup>1,6\*</sup>, Sébastien Rubin<sup>2</sup>, Pierre Sioniac<sup>1</sup>, Dominique Breilh<sup>3,4</sup> and Matthieu Biais<sup>1,5</sup>

**Keywords:** Augmented renal clearance, Kinetic glomerular filtration rate, Piperacillin, Critical care

In the critical care setting, augmented renal clearance (ARC) is increasingly recognized as one of the leading causes of subtherapeutic antibiotic exposure [1]. However, commonly used formulas for estimating glomerular filtration rate (GFR) are inaccurate in patients with ARC and the 24-h urinary creatinine clearance ( $Cr_{CL}$ ) remains the best available approach for optimizing empirical antimicrobial therapy [2]. On the other hand, no study has evaluated the clinical and prognostic value of the kinetic estimated GFR (KeGFR) in this context. We thus aimed to determine whether KeGFR could be a reliable alternative to measured  $Cr_{CL}$  in critically ill patients needing early initiation of an appropriate piperacillin dosing regimen.

For this purpose, we retrospectively analyzed 60 consecutive patients who underwent 24-h urinary  $Cr_{CL}$  measurements and therapeutic drug monitoring during the first 3 days of antimicrobial therapy of piperacillin administered 16 g/day continuously. The protocol pertaining to this substudy has been published elsewhere [3]. As previously described, the corresponding KeGFR was calculated as follows:  $\frac{\text{Baseline sCr} \times \text{eGFR}}{\text{Mean sCr}} \times \left(1 - \frac{24 \times \Delta \text{sCr}}{\Delta t \times \text{Max} \Delta \text{sCr} / \text{Day}}\right)$  with eGFR derived from the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation using serum creatinine (sCr) before admission,  $\Delta t$  fixed at 24 h

between two sCr measurements, and maximal sCr increase per day approximated to 133  $\mu\text{mol/L}$  [4]. ARC was defined by a measured  $Cr_{CL} \geq 130 \text{ mL/min/1.73 m}^2$ . Piperacillin underdosing was arbitrarily defined by a free drug concentration  $\leq 32 \mu\text{g/ml}$  at steady state.

Among the 180 samples analyzed, the incidence of ARC was 48% (median  $Cr_{CL}$  values = 124 [83–170]  $\text{mL/min/1.73 m}^2$ ) and the incidence of piperacillin underdosing was 51% (median piperacillin concentrations = 32 [22–47]  $\mu\text{g/ml}$ ). The diagnostic agreement between KeGFR and  $Cr_{CL}$  was only moderate ( $\kappa = 0.48$  [95% confidence interval 0.4–0.55]) (Fig. 1). Comparison between KeGFR and  $Cr_{CL}$  showed a mean bias of  $-8.7 \text{ mL/min/1.73 m}^2$  and limit of agreement from  $-99 \text{ mL/min/1.73 m}^2$  to  $82 \text{ mL/min/1.73 m}^2$ . Finally, the area under the ROC curve generated for KeGFR was significantly lower than the one generated for measured  $Cr_{CL}$  for prediction of piperacillin underdosing (0.76 [0.68–0.83] vs 0.85 [0.79–0.91],  $p = 0.03$ ; Fig. 2).

In conclusion, KeGFR is not interchangeable with measured  $Cr_{CL}$  for prediction of piperacillin underexposure in critically ill patients with ARC. Also, scarce data may suggest a better predictive value of Cockcroft-Gault compared to MDRD (Modification of Diet in Renal Disease Study) or CKD-EPI for identifying patients with ARC [5]; a measured  $CL_{CR}$  should be performed to accurately guide drug dosing. This study emphasizes the need for dosing adjustment and therapeutic drug monitoring in patients with ARC.


\* Correspondence: [cedric.carrie@chu-bordeaux.fr](mailto:cedric.carrie@chu-bordeaux.fr)

<sup>1</sup>Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France


<sup>6</sup>Surgical and Trauma Intensive Care Unit, Anesthesiology and Critical Care Department, Hôpital Pellegrin, CHU Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France

Full list of author information is available at the end of the article





**Fig. 1** Correlation between measured Cr<sub>CL</sub> and KeGFR ( $r^2 = 0.54, p < 0.0001$ ) and repartition of samples with (white circles) or without (black circles) piperacillin underdosing, defined by an unbound concentration  $\leq 32 \mu\text{g/ml}$ . ARC was defined by a measured Cr<sub>CL</sub> or a KeGFR  $\geq 130 \text{ ml/min/1.73 m}^2$ . Samples in the gray shaded area are considered to be well classified



**Fig. 2** Receiver operating characteristics (ROC) curves evaluating the ability of KeGFR and measured Cr<sub>CL</sub> to predict piperacillin underdosing. Areas under ROC curves between KeGFR and measured Cr<sub>CL</sub> were compared using the Handley approach. Piperacillin underdosing was defined by a free drug concentration  $\leq 32 \mu\text{g/ml}$

**Abbreviations**

ARC: Augmented renal clearance;  $Cr_{CL}$ : Creatinine clearance; GFR: Glomerular filtration rate; KeGFR: Kinetic estimated glomerular filtration rate; MIC: Minimum inhibitory concentration; ROC: Receiver operating characteristic; sCr: Serum creatinine

**Acknowledgements**

The authors thank Nicolas d'Houdain for his contribution to sample storage, preparation, and quantification.

**Funding**

Only departmental funds were used for this study. No external funds were obtained.

**Availability of data and materials**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors' contributions**

CC and SR designed the study. CC and PS recruited patients and collected the data. CC and MB performed statistical analysis and wrote the manuscript. DB was in charge of sample preparation, storage and quantification. SR, DB, and MB have personally reviewed the data and confirmed that the methods are clearly described and that they are a fair way to report the results. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

Ethics approval was obtained from the Institutional Review Board (Comite de Protection des Personnes Sud-Ouest et Outre Mer III, Bordeaux, France; protocol number DC 2016/147), which waived the need for written consent. Patients or next of kin were orally informed of the goal and design of the study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

<sup>1</sup>Anesthesiology and Critical Care Department, CHU Bordeaux, 33000 Bordeaux, France. <sup>2</sup>Nephrology Department, CHU Bordeaux, 33000 Bordeaux, France. <sup>3</sup>Pharmacy and Clinical Pharmacy Department, CHU Bordeaux, 33000 Bordeaux, France. <sup>4</sup>Pharmacokinetics and PK/PD Group INSERM 1034, University Bordeaux, 33000 Bordeaux, France. <sup>5</sup>University Bordeaux Segalen, 33000 Bordeaux, France. <sup>6</sup>Surgical and Trauma Intensive Care Unit, Anesthesiology and Critical Care Department, Hôpital Pellegrin, CHU Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux Cedex, France.

Received: 22 May 2018 Accepted: 3 July 2018

Published online: 23 July 2018

**References**

1. Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, Kirkpatrick CM, Kruger PS, Paterson DL, Roberts MS, Roberts JA. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? *Crit Care*. 2015;19:28.
2. Barletta JF, Mangram AJ, Byrne M, Hollingworth AK, Sucher JF, Ali-Osman FR, Shirah GR, Dzandu JK. The importance of empiric antibiotic dosing in critically ill trauma patients: are we under-dosing based on augmented renal clearance and inaccurate renal clearance estimates? *J Trauma Acute Care Surg*. 2016;81(6):1115–21.
3. Carrié C, Petit L, d'Houdain N, Sauvage N, Cottenceau V, Lafitte M, Fountenteze C, Hisz Q, Menu D, Legeron R, Breilh D, Sztark F. Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of  $\beta$ -lactams administered by continuous infusion: a prospective observational study. *Int J Antimicrob Agents*. 2018;51(3):443–9.

4. Dewitte A, Joannès-Boyau O, Sidobre C, Fleureau C, Bats ML, Derache P, Leuillet S, Ripoché J, Combe C, Ouattara A. Kinetic eGFR and novel AKI biomarkers to predict renal recovery. *Clin J Am Soc Nephrol*. 2015;10(11):1900–10.
5. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. *Crit Care*. 2011;15(3):R139.